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Introduction
Schnitzler’s syndrome is a chronic disabling autoinflam-
matory disorder, characterised by chronic urticaria, para-
proteinemia and systemic inflammation. The interleukin
(IL) 1 receptor antagonist anakinra is a very effective
treatment, but requires daily injection and blocks both
IL-1a and IL-1b. Canakinumab is a selective human
monoclonal anti-IL-1b antibody with a long half-life.
Objectives
We investigated the long-term efficacy and safety of
canakinumab in Schnitzler’s syndrome.
Methods
In an open-label, single-treatment arm trial, eight patients
with Schnitzler’s syndrome received monthly injections
with 150 mg canakinumab subcutaneously for 6 months,
followed by a 3-month observation period. Primary out-
come was complete or clinical remission at day 14. Second-
ary outcome measures included inflammatory markers,
quality of life, time to relapse, safety and tolerability.
Results
After stopping anakinra, patients developed moderate to
severe clinical symptoms. Canakinumab induced com-
plete or clinical remission at day 14 in all eight patients.
Median C-reactive protein concentrations decreased from
169 mg/l at baseline to less than 10 mg/l on day 14 and
remained low or undetectable. One patient discontinued
participation on day 39 because of return of symptoms
while all others remained in complete or clinical remis-
sion during the 6-month treatment period. Relapse after
last canakinumab dose occurred within 3 months in four
patients. For two patients, remission continued several
months post-study. Five patients reported at least one
adverse event, predominantly mild upper respiratory tract
infections. One patient died in a traffic accident.
Conclusion
In this 9-month study, monthly 150 mg canakinumab
injection was an effective and well-tolerated treatment
for Schnitzler’s syndrome. Our data demonstrate that
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